Gingival crevicular fluid and serum matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 levels in renal transplant patients undergoing different immunosuppressive therapy

• Published in: Journal of clinical periodontology Vol. 35; no. 3; pp. 221 - 229
• Main Authors: Emingil, Gülnur, Afacan, Beral, Tervahartiala, Taina, Töz, Hüseyin, Atilla, Gül, Sorsa, Timo
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.03.2008; Blackwell
• Subjects: Adolescent; Adult; Biological and medical sciences; Cyclosporine - adverse effects; Epidemiologic Methods; Facial bones, jaws, teeth, parodontium: diseases, semeiology; Female; gingival crevicular fluid; Gingival Crevicular Fluid - chemistry; Gingival Overgrowth - chemically induced; Gingival Overgrowth - diagnostic imaging; gingival overgrowth/pathogenesis; Gingivitis - diagnostic imaging; Humans; Immunocompromised Host; Immunosuppressive Agents - adverse effects; Kidney Transplantation - adverse effects; Male; Matrix Metalloproteinase 8 - blood; Medical sciences; Middle Aged; MMP-8; MMP‐8, TIMP‐1; Non tumoral diseases; Otorhinolaryngology. Stomatology; Radiography; Tacrolimus - adverse effects; TIMP-1; Tissue Inhibitor of Metalloproteinase-1 - blood; Graft(material); TIMP-1; Matrix metalloproteinase 8; Pathogenesis; Crevicular fluid; Metalloendopeptidases; Transplantation; Kidney; Gingivitis hyperplasia; gingival crevicular fluid; gingival overgrowth/pathogenesis; MMP-8; Tissue; Surgery; Graft; Serum; Interstitial collagenase; Gingival fluid; Human; Enzyme; Stomatology; Dentistry; Peptidases; Periodontal disease; Treatment; Neutrophil collagenase; Hydrolases; Immunosuppressive agent
• ISSN: 0303-6979; 1600-051X; 1600-051X
• DOI: 10.1111/j.1600-051X.2007.01192.x

Aim: We investigated gingival crevicular fluid (GCF) and serum matrix metalloproteinase‐8 (MMP‐8) and tissue inhibitor of matrix metalloproteinase‐1 (TIMP‐1) levels from renal transplant patients receiving cyclosporine‐A (CsA) and having gingival overgrowth (GO), from patients receiving CsA therapy and having no GO and patients receiving tacrolimus therapy. Material and Methods: GCF samples were collected from sites with GO (GO+) and without GO (GO−) in CsA patients having GO; and GO− sites in CsA patients having no GO; sites from tacrolimus, gingivitis and healthy subjects. GCF and serum MMP‐8 and TIMP‐1 levels were determined by a time‐resolved immunofluorometric assay (IFMA) and enzyme‐linked immunosorbent assay. Results: GO+ sites in CsA patients having GO had elevated GCF MMP‐8 levels compared with those of CsA patients having no GO, tacrolimus and healthy subjects (p<0.005), but these levels were similar to those of gingivitis. The GCF MMP‐8 level was higher in GO+ compared with GO− sites in CsA patients having GO (p<0.05). GCF TIMP‐1 levels were similar between groups. Tacrolimus patients had lower GCF MMP‐8 levels than gingivitis (p<0.005), but levels similar to the healthy group. Conclusion: These results show that CsA and tacrolimus therapy has no significant effect on GCF MMP‐8 levels, and gingival inflammation seems to be the main reason for their elevations.